Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
- Conditions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
- Target Recruit Count
- 83
- Registration Number
- NCT00283179
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 111
- Registration Number
- NCT00277654
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
- Conditions
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2006-05-08
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 100
- Registration Number
- NCT00272584
- Locations
- 🇨🇦
UBC Hospital, Vancouver, British Columbia, Canada
Risperidone LA Heathcare Resource Study
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT00272597
- Locations
- 🇨🇦
Riverview Hospital, Coquitlam, British Columbia, Canada
SPECT Study With SB-773812 In Schizophrenic Patients
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT00269035
- Locations
- 🇪🇸
GSK Investigational Site, Vic (Barcelona), Spain
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
- Conditions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 118
- Registration Number
- NCT00266552
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 80
- Registration Number
- NCT00261508
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 250
- Registration Number
- NCT00255879
- Locations
- 🇺🇸
University of California, San Diego Division of Geriatric Psychiatry, San Diego, California, United States
A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT00254930
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Target Recruit Count
- 439
- Registration Number
- NCT00253162
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.